Table 3.
Gene combination for the CFD and CFH polymorphisms in patients with RPL and controls.
| Genotype combination | Controls (n = 384) |
RPL Patients (n = 412) |
AOR (95% CI) * | p | FDR-p |
|---|---|---|---|---|---|
| CFD rs2230216C>G/CFH rs1065489G>T | |||||
| CC/GG | 86 (22.4) | 100 (24.3) | |||
| CC/GT | 151 (39.3) | 157 (38.1) | 0.897 (0.623–1.000) | 0.561 | 0.813 |
| CC/TT | 69 (18.0) | 60 (14.6) | 0.747 (0.476–1.173) | 0.205 | 0.646 |
| CG/GG | 23 (6.0) | 23 (5.6) | 0.859 (0.450–1.640) | 0.645 | 0.813 |
| CG/GT | 44 (11.5) | 49 (11.9) | 0.951 (0.575–1.571) | 0.843 | 0.885 |
| CG/TT | 5 (1.3) | 21 (5.1) | 3.443 (1.239–9.569) | 0.018 | 0.113 |
| GG/GT | 4 (1.0) | 2 (0.5) | 0.421 (0.075–2.369) | 0.326 | 0.685 |
| GG/TT | 2 (0.5) | 0 (0.0) | N./A | N./A | N./A |
| CFD rs2230216C>G/CFH rs1061170T>C | |||||
| CC/TT | 260 (67.7) | 283 (68.7) | 1.000 (reference) | ||
| CC/TC | 46 (12.0) | 34 (8.3) | 0.673 (0.419–1.082) | 0.102 | 0.293 |
| CG/TT | 60 (15.6) | 85 (20.6) | 1.277 (0.880–1.000) | 0.199 | 0.293 |
| CG/TC | 12 (3.1) | 8 (1.9) | 0.607 (0.244–1.511) | 0.283 | 0.297 |
| GG/TT | 5 (1.3) | 2 (0.5) | 0.347 (0.066–1.811) | 0.209 | 0.293 |
| GG/TC | 1 (0.3) | 0 (0.0) | N./A | N./A | N./A |
| CFH rs1065489G>T/CFH rs1061170T>C | |||||
| GG/TT | 92 (16.4) | 108 (32.6) | 1.000 (reference) | ||
| GG/TC | 17 (3.0) | 15 (4.5) | 0.752 (0.356–1.588) | 0.454 | 0.563 |
| GT/TT | 161 (28.6) | 188 (56.8) | 0.991 (0.699–1.404) | 0.957 | 0.804 |
| GT/TC | 38 (6.8) | 20 (6.0) | 0.439 (0.238–0.810) | 0.008 | 0.034 |
| TT/TT | 72 (18.8) | 74 (18.0) | 0.863 (0.563–1.325) | 0.501 | 0.563 |
| TT/TC | 4 (1.0) | 7 (1.7) | 1.489 (0.422–5.246) | 0.536 | 0.563 |
* The odds ratio was adjusted by age. CFD, complement factor D; CFH, complement factor H; RPL, recurrent pregnancy loss; OR, odds ratio; 95% CI, 95% confidence interval; FDR, false discovery rate.